Clinical Trial Update: Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms [Phase 4]

View source ↗

Summary

A Phase 4 study evaluated whether weight-based dosing of plerixafor is preferable to a fixed dose in adults with non-Hodgkin lymphoma weighing under 70 kg; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Mozobil (plerixafor)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Non-Hodgkin's Lymphoma | Phase 4 | Status: COMPLETED | Results posted: 2014-01-31